Feverfew

About Feverfew

Tanacetum parthenium is a bushy perennial herb in the daisy family, native to Asia Minor and the Balkans and naturalized throughout Europe and North America. Its common name — feverfew — derives from the Latin febrifugia (fever-reducer), reflecting its historical use as an antipyretic before the discovery of aspirin. The plant's small, white-petaled daisy flowers and serrated, strongly aromatic leaves are distinctive; the leaves have a bitter, pungent taste that is unmistakable and off-putting in direct consumption, which is why many feverfew preparations historically involved chewing the fresh leaf with bread to mask the bitterness.

Feverfew's pharmacology is dominated by parthenolide, a sesquiterpene lactone present at 0.2-0.9% in the fresh leaf that is responsible for both the plant's therapeutic effects and its contact dermatitis risk. Parthenolide inhibits platelet aggregation, inhibits the release of serotonin from platelets, and blocks NF-kB activation — an inflammatory transcription factor central to prostaglandin synthesis. This combination of mechanisms directly addresses migraine physiology, where both platelet serotonin release and prostaglandin-driven inflammation of the trigeminal vascular system are central to the cascade.

The plant is cultivated or grows wild across Western Europe and has been naturalized widely in North America. It is one of the few herbs for which human clinical trial evidence has been sufficient to generate a systematic review recommendation specifically for migraine prevention — as opposed to acute treatment — which is the pharmacologically appropriate use given parthenolide's mechanism.

What are the traditional uses of Feverfew?

Feverfew's medicinal use in Europe dates to at least the 1st century CE. Dioscorides in De Materia Medica describes Parthenium as useful for 'all hot inflammations' and for women's conditions. John Gerard's 1597 Herball recommends it for 'melancholy and cold humours,' and John Parkinson's 1640 Theatrum Botanicum describes its use for headache, 'pain of the whole body,' and as a bitter tonic.

In 16th-19th century European folk medicine, feverfew was a standard domestic remedy for headaches, fever, and gynecological complaints including painful and irregular menstruation. The traditional Welsh use of feverfew for headache is particularly well-documented; the 1978 case of a Welsh doctor's wife whose migraines resolved after daily fresh-leaf consumption is the origin of the first modern clinical investigation of feverfew for migraine, published by Johnson et al. in the British Medical Journal in 1985.

In traditional Ayurveda, Tanacetum parthenium does not appear in classical texts — it is a European and Middle Eastern plant outside the classical Indian pharmacopoeia. Contemporary Ayurvedic practitioners work with it primarily for its documented migraine-prevention application, applying Ayurvedic constitutional frameworks to a Western plant on the basis of its pharmacological profile.

What does modern research say about Feverfew?

The feverfew-migraine evidence base is the most coherent in the herb's clinical literature. The first controlled trial (Johnson, Kadam, Hylands, Hylands, British Medical Journal, 1985) enrolled 17 patients who had been taking raw feverfew daily and randomized them to continue or switch to placebo. The placebo group experienced significant increases in migraine frequency and severity. A subsequent double-blind crossover trial (Murphy, Heptinstall, Mitchell, Lancet, 1988) randomized 72 patients to 82 mg dried whole leaf or placebo for four months and found significant reductions in migraine attack frequency (24% reduction), severity, and associated symptoms including nausea and vomiting.

A 2004 Cochrane review (Pittler and Ernst) analyzed five randomized double-blind trials of feverfew for migraine prevention. Four of the five trials showed a directional benefit for feverfew over placebo; the reviewers concluded the evidence suggested a benefit but was limited by methodological heterogeneity and small sample sizes. A 2011 systematic review in the American Family Physician similarly concluded that feverfew showed moderate evidence for migraine prevention at doses of at least 100 mg/day of standardized leaf extract.

Parthenolide's mechanism has been studied extensively in vitro: serotonin release inhibition from platelets (Heptinstall et al., Journal of Pharmacy and Pharmacology, 1988), prostaglandin synthesis inhibition, and NF-kB blockade (Kwok et al., Blood, 2001) are the three best-documented molecular actions. These map directly onto the platelet-serotonin and neuroinflammatory pathways currently understood to underlie migraine.

A 2006 RCT by Diener, Pfaffenrath, Schnitker, Friede, Henneicke-von Zepelin, published in Cephalalgia, tested a specific CO2-extract of feverfew standardized to 6.25 mg parthenolide and found significant reductions in migraine frequency compared to placebo in 147 patients over 16 weeks — the largest well-controlled trial to date.

How does Feverfew affect the doshas?

Feverfew's primary application in an Ayurvedic framework is for Pitta-type headaches and migraines. The association of pitta dosha with heat, inflammation, sharpness, and the raktavaha (blood) system maps closely onto migraine's inflammatory vascular mechanism. Feverfew's bitter, pitta-cooling, blood-regulating action is pharmacologically aligned with this pattern.

For Vata types who experience migraines, feverfew's circulation-regulating and serotonin-modulating effects remain relevant, but the herb's bitter cooling quality needs to be balanced with warming, nourishing vata herbs in the broader protocol. Feverfew alone can be drying and cold for vata constitutions.

Kapha types are the least likely to benefit from feverfew and most likely to have its cold, bitter nature mismatch their constitution. Kapha-type headaches tend to be dull, heavy, and sinus-related rather than the sharp, throbbing, light-sensitive migraine pattern that feverfew addresses.

Which tissues and channels does Feverfew affect?

What is the recommended dosage for Feverfew?

For migraine prevention: 125-250 mg dried leaf (standardized to 0.2-0.4% parthenolide) once daily. The Diener 2006 RCT used 6.25 mg parthenolide (CO2 extract). Traditional fresh-leaf use: 2-3 medium leaves daily. Consistent daily use for 3-6 months is required to assess preventive efficacy; benefit typically accumulates rather than appearing immediately. Discontinuation should be gradual — abrupt stopping is associated with 'post-feverfew syndrome' (return of headaches, joint pain) in some users who have taken it for extended periods.

What herbs combine well with Feverfew?

Feverfew for migraine prevention combines clinically with magnesium and riboflavin (vitamin B2) — a combination studied in the migraine prevention literature that covers three distinct mechanisms: platelet-serotonin stabilization (feverfew), neurovascular stability (magnesium), and mitochondrial energy production (riboflavin). A 2000 paper by Mauskop and Varughese in Headache proposed this multi-modal protocol based on the independent evidence base for each component.

With ginger for the nausea component of migraine — ginger's 5-HT3 antagonist activity addresses the nausea that accompanies many migraine attacks, complementing feverfew's prevention at the platelet-vascular level. The combination covers both the vascular-inflammatory and the gastric-nausea dimensions of migraine.

In Ayurvedic-integrated migraine protocols, feverfew is combined with brahmi — brahmi addresses the nervous system dimension of pitta-driven mental heat and hypersensitivity while feverfew modulates the vascular-platelet component. Together they address migraine from both the manovaha (mental channels) and raktavaha (blood channels) perspectives.

When is the best season to use Feverfew?

Feverfew is most relevant during summer (Grishma) and Sharad (autumn) — the pitta-dominant seasons when heat drives the inflammatory vascular patterns that characterize pitta-type migraines. In Ayurvedic observation, migraine frequency tends to increase in hot weather; feverfew's preventive use is most consistent with these seasonal increases.

As a preventive herb requiring consistent daily use, feverfew is appropriate year-round for individuals with chronic migraine patterns. The fresh leaf is available from the garden through summer and early autumn; dried preparations provide year-round access.

How do I choose quality Feverfew?

Feverfew standardization is critical. Parthenolide is the marker compound, and commercial products vary dramatically in content — many bulk-dried feverfew products contain less than 0.1% parthenolide (below the established threshold), rendering them pharmacologically inert for migraine prevention. Source products that specify parthenolide content at minimum 0.2% (European Pharmacopoeia standard). MigraFew, the CO2-extracted standardized product used in the Diener 2006 trial, is a reference product. Canadian and European products more consistently meet parthenolide standards than many US products due to regulatory requirements. Freeze-dried preparations preserve parthenolide better than conventionally dried herb. Avoid products that do not specify parthenolide content on the label.

Affiliate link — we earn a small commission at no extra cost to you.